Atossa Genetics, Inc.
(NASDAQ : ATOS)

( )
ATOS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
MDTMedtronic PLC
1.14%88.770.6%$434.09m
TMOThermo Fisher Scientific Inc.
2.38%271.671.0%$433.69m
ISRGIntuitive Surgical, Inc.
0.37%485.372.4%$388.14m
BDXBecton, Dickinson and Company
0.75%235.731.1%$376.82m
ABTAbbott Laboratories
0.32%76.270.8%$367.42m
ALGNAlign Technology, Inc.
-0.27%318.826.3%$341.92m
BSXBoston Scientific Corporation
0.11%37.741.1%$309.81m
ABMDABIOMED, Inc.
1.97%265.483.3%$261.70m
SYKStryker Corporation
0.25%185.921.3%$211.06m
BAXBaxter International Inc.
0.37%75.581.7%$197.08m
EWEdwards Lifesciences Corporation
0.38%172.651.2%$193.00m
WATWaters Corporation
0.50%207.183.8%$157.08m
ZBHZimmer Biomet Holdings, Inc.
-0.83%115.151.7%$144.43m
DXCMDexCom, Inc.
0.14%118.758.3%$130.28m
IDXXIDEXX Laboratories, Inc.
0.42%250.383.7%$124.02m

Company Profile

Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.